Anti-Spike protein [EY6A]

Absolute Antibody

Anti-Spike protein [EY6A]

9

This antibody binds tightly (KD of 2 nM) to the receptor binding domain (RBD) the of the SARS-CoV-2. It also cross reacts with SARS-CoV-1. This antibody recognizes a highly conserved epitope on away from the ACE2 receptor binding domain.

EY6A binds S1 domain of SARS-CoV-2 and also cross reacts with SARS-CoV-1. The binding was confirmed by ELISA. Further confirmation of binding of EY6A to SARS-CoV-2 infected cells was done by immunofluorescence. Surface plasmon resonance (SPR) measurements for EY6A Fab showed high affinity binding to immobilised SARS-CoV-2 RBD (KD = 2 nM). EY6A did not completely block binding of ACE2 to RBD, but was successful in neutralizing SARS-CoV-2 infection in Vero E6 cells (Zhou et al., 2020).

ImmunoFluorescence, ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

EY6A

S

surface glycoprotein

GU280_gp02; spike glycoprotein; surface glycoprotein

Human

Spike glycoprotein

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203